Genome-wide prediction of vaccine targets for human herpes simplex viruses using Vaxign reverse vaccinology

BMC Bioinformatics

Volumn 14, Issue SUPPL4, 2013, Pages

  Xiang, Zuoshuang ^a   He, Yongqun ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPARATIVE ANALYSIS; COMPUTATIONAL PREDICTIONS; ENVELOPE GLYCOPROTEINS; GENOME SEQUENCES; HERPES SIMPLEX VIRUS; INFECTIOUS AGENTS; REVERSE VACCINOLOGY; VACCINE DEVELOPMENT;

EPITOPES; FORECASTING; GENES; PROTEINS; SCAFFOLDS (BIOLOGY); STRAIN; VIRUSES;

VACCINES;

CAPSID PROTEIN; EPITOPE; HERPES SIMPLEX VACCINE;

ARTICLE; BIOLOGY; CLASSIFICATION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; SIMPLEXVIRUS; VIRUS GENOME;

CAPSID PROTEINS; COMPUTATIONAL BIOLOGY; EPITOPES; GENOME, VIRAL; HERPES SIMPLEX VIRUS VACCINES; HUMANS; SIMPLEXVIRUS;

MLCS; MLOWN;

EID: 84879524693     PISSN: None     EISSN: 14712105     Source Type: Journal    
DOI: 10.1186/1471-2105-14-S4-S2     Document Type: Article

References (39)

1. Watanabe D. Medical application of herpes simplex virus. J Dermatol Sci 2010, 57(2):75-82. 10.1016/j.jdermsci.2009.10.014, 19939634.
2. Dasgupta G, Chentoufi AA, Nesburn AB, Wechsler SL, BenMohamed L. New concepts in herpes simplex virus vaccine development: notes from the battlefield. Expert Rev Vaccines 2009, 8(8):1023-1035. 10.1586/erv.09.60, 2760836, 19627185.
3. Koelle DM. Vaccines for herpes simplex virus infections. Curr Opin Investig Drugs 2006, 7(2):136-141.
4. Koelle DM, Corey L. Herpes simplex: insights on pathogenesis and possible vaccines. Annu Rev Med 2008, 59:381-395. 10.1146/annurev.med.59.061606.095540, 18186706.
5. Jones CA, Cunningham AL. Development of prophylactic vaccines for genital and neonatal herpes. Expert Rev Vaccines 2003, 2(4):541-549. 10.1586/14760584.2.4.541, 14711338.
6. Rajcani J, Durmanova V. Developments in herpes simplex virus vaccines: old problems and new challenges. Folia Microbiol (Praha) 2006, 51(2):67-85. 10.1007/BF02932160, 16821715.
7. Rappuoli R. Reverse vaccinology. Curr Opin Microbiol 2000, 3(5):445-450. 10.1016/S1369-5274(00)00119-3, 11050440.
8. Pizza M, Scarlato V, Masignani V, Giuliani MM, Arico B, Comanducci M, Jennings GT, Baldi L, Bartolini E, Capecchi B, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000, 287(5459):1816-1820. 10.1126/science.287.5459.1816, 10710308.
9. Ariel N, Zvi A, Grosfeld H, Gat O, Inbar Y, Velan B, Cohen S, Shafferman A. Search for potential vaccine candidate open reading frames in the Bacillus anthracis virulence plasmid pXO1: in silico and in vitro screening. Infect Immun 2002, 70(12):6817-6827. 10.1128/IAI.70.12.6817-6827.2002, 133087, 12438358.
10. Wizemann TM, Heinrichs JH, Adamou JE, Erwin AL, Kunsch C, Choi GH, Barash SC, Rosen CA, Masure HR, Tuomanen E, et al. Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Infect Immun 2001, 69(3):1593-1598. 10.1128/IAI.69.3.1593-1598.2001, 98061, 11179332.
11. Betts JC. Transcriptomics and proteomics: tools for the identification of novel drug targets and vaccine candidates for tuberculosis. IUBMB Life 2002, 53(4-5):239-242. 10.1080/15216540212651, 12121002.
12. Manque PA, Tenjo F, Woehlbier U, Lara AM, Serrano MG, Xu P, Alves JM, Smeltz RB, Conrad DH, Buck GA. Identification and immunological characterization of three potential vaccinogens against Cryptosporidium. Clin Vaccine Immunol 2011, 3209039, 21918117.
13. He Y, Xiang Z, Mobley HL. Vaxign: the first web-based vaccine design program for reverse vaccinology and applications for vaccine development. Journal of Biomedicine and Biotechnology 2010, 2010(2010). Article ID 297505, 15 pages, 2910479, 20671958.
14. Xiang Z, He Y. Vaxign: a web-based vaccine target design program for reverse vaccinology. Procedia in Vaccinology 2009, 1(1):23-29.
15. He Y, Xiang Z. Bioinformatics analysis of Brucella vaccines and vaccine targets using VIOLIN. Immunome Res 2010, 6(Suppl 1):S5. 10.1186/1745-7580-6-S1-S5, 2946783, 20875156.
16. McGeoch DJ, Dalrymple MA, Davison AJ, Dolan A, Frame MC, McNab D, Perry LJ, Scott JE, Taylor P. The complete DNA sequence of the long unique region in the genome of herpes simplex virus type 1. J Gen Virol 1988, 69(Pt 7):1531-1574.
17. Dolan A, Jamieson FE, Cunningham C, Barnett BC, McGeoch DJ. The genome sequence of herpes simplex virus type 2. J Virol 1998, 72(3):2010-2021. 109494, 9499055.
18. He Y, Rappuoli R, De Groot AS, Chen RT. Emerging vaccine informatics. J Biomed Biotechnol 2010, 2010:218590. 3134832, 21772787.
19. Brown JC, Newcomb WW. Herpesvirus capsid assembly: insights from structural analysis. Curr Opin Virol 2011, 1(2):142-149. 10.1016/j.coviro.2011.06.003, 3171831, 21927635.
20. Meshkat Z, Roostaee MH, Soleimanjahi M, Zandi K. Evaluation of antibodies against glycoprotein D (gD) and glycoprotein G (gG) in HSV-1 infected individuals' serum samples. Eur Rev Med Pharmacol Sci 2012, 16(4):499-502.
21. Dingwell KS, Doering LC, Johnson DC. Glycoproteins E and I facilitate neuron-to-neuron spread of herpes simplex virus. J Virol 1995, 69(11):7087-7098. 189628, 7474128.
22. Koshizuka T, Goshima F, Takakuwa H, Nozawa N, Daikoku T, Koiwai O, Nishiyama Y. Identification and characterization of the UL56 gene product of herpes simplex virus type 2. J Virol 2002, 76(13):6718-6728. 10.1128/JVI.76.13.6718-6728.2002, 136277, 12050385.
23. Li Y, Zhang C, Chen X, Yu J, Wang Y, Yang Y, Du M, Jin H, Ma Y, He B, et al. ICP34.5 protein of herpes simplex virus facilitates the initiation of protein translation by bridging eukaryotic initiation factor 2alpha (eIF2alpha) and protein phosphatase 1. J Biol Chem 2011, 286(28):24785-24792. 10.1074/jbc.M111.232439, 3137054, 21622569.
24. Burgos JS, Serrano-Saiz E, Sastre I, Valdivieso F. ICP47 mediates viral neuroinvasiveness by induction of TAP protein following intravenous inoculation of herpes simplex virus type 1 in mice. J Neurovirol 2006, 12(6):420-427. 10.1080/13550280601009546, 17162658.
25. Warner SC, Desai P, Person S. Second-site mutations encoding residues 34 and 78 of the major capsid protein (VP5) of herpes simplex virus type 1 are important for overcoming a blocked maturation cleavage site of the capsid scaffold proteins. Virology 2000, 278(1):217-226. 10.1006/viro.2000.0657, 11112496.
26. Sheaffer AK, Newcomb WW, Brown JC, Gao M, Weller SK, Tenney DJ. Evidence for controlled incorporation of herpes simplex virus type 1 UL26 protease into capsids. J Virol 2000, 74(15):6838-6848. 10.1128/JVI.74.15.6838-6848.2000, 112201, 10888623.
27. Huffman JB, Newcomb WW, Brown JC, Homa FL. Amino acids 143 to 150 of the herpes simplex virus type 1 scaffold protein are required for the formation of portal-containing capsids. J Virol 2008, 82(13):6778-6781. 10.1128/JVI.00473-08, 2447111, 18417585.
28. Wang P, Sidney J, Dow C, Mothe B, Sette A, Peters B. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput Biol 2008, 4(4):e1000048. 10.1371/journal.pcbi.1000048, 2267221, 18389056.
29. Yu NY, Wagner JR, Laird MR, Melli G, Rey S, Lo R, Dao P, Sahinalp SC, Ester M, Foster LJ, et al. PSORTb 3.0: improved protein subcellular localization prediction with refined localization subcategories and predictive capabilities for all prokaryotes. Bioinformatics (Oxford, England) 2010, 26(13):1608-1615. 10.1093/bioinformatics/btq249, 2887053, 20472543.
30. Xiang Z, Todd T, Ku KP, Kovacic BL, Larson CB, Chen F, Hodges AP, Tian Y, Olenzek EA, Zhao B, et al. VIOLIN: vaccine investigation and online information network. Nucleic Acids Res 2008, 36(Database):D923-928. 2238972, 18025042.
31. Yang B, Sayers S, Xiang Z, He Y. Protegen: a web-based protective antigen database and analysis system. Nucleic Acids Res 2010, 3013795, 20959289.
32. He Y, Xiang Z. Bioinformatics analysis of bacterial protective antigens in manually curated Protegen database. Procedia in Vaccinology 2012, 6:3-9.
33. Sayers S, Ulysse G, Xiang Z, He Y. Vaxjo: a web-based vaccine adjuvant database and its application for analysis of vaccine adjuvants and their uses in vaccine development. J Biomed Biotechnol 2012, 2012:831486. 3312338, 22505817.
34. He Y, Cowell L, Diehl AD, Mobley HL, Peters B, Ruttenberg A, Scheuermann RH, Brinkman RR, Courtot M, Mungall C, et al. VO: Vaccine Ontology. The 1st International Conference on Biomedical Ontology (ICBO 2009) Nature Precedings 2009, Buffalo, NY, USA, July 24-26, 2009 2009., http://precedings.nature.com/documents/3553/version/1
35. Ozgur A, Xiang Z, Radev D, He Y. Mining of vaccine-associated IFN-γ gene interaction networks using the Vaccine Ontology. Journal of Biomedical Semantics 2011, 17( Suppl 2). 3102897, 21624163., http://www.jbiomedsem.com/qc/content/2/S2/S8
36. Hur J, Xiang Z, Feldman EL, He Y. Ontology-based Brucella vaccine literature indexing and systematic analysis of gene-vaccine association network. BMC Immunol 2011, 12:49. 10.1186/1471-2172-12-49, 3180695, 21871085.
37. Pruitt KD, Tatusova T, Maglott DR. NCBI Reference Sequence (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins. Nucleic Acids Res 2005, 33(Database):D501-504. 539979, 15608248.
38. Benson DA, Karsch-Mizrachi I, Lipman DJ, Ostell J, Wheeler DL. GenBank. Nucleic Acids Res 2006, 34(Database):D16-20. 1347519, 16381837.
39. Matthews BW. Comparison of the predicted and observed secondary structure of T4 phage lysozyme. Biochim Biophys Acta. 1975, 205(2):442-451.